2. Vías de señalización
  3. Immunology/Inflammation
  4. NOD-like Receptor (NLR)
  5. NOD2 Isoform

NOD2

NOD2 (nucleotide-binding oligomerization domain-containing protein 2) is a cytosolic pattern-recognition receptor of the NLR family that detects muramyl dipeptide (MDP) derived from bacterial peptidoglycan and functions as a central regulator of innate immune surveillance[1][2]. Upon MDP recognition, NOD2 undergoes conformational activation and recruits RIPK2/RIP2 through CARD-CARD interactions, initiating signaling cascades that activate NF-κB and MAPK pathways and drive transcriptional programs involved in antimicrobial and inflammatory responses[3][4][5]. Mechanistically, RIPK2-dependent signaling promotes downstream kinase activation and cytokine production, linking microbial sensing to host defense and immune homeostasis[3][4][6]. In disease contexts, NOD2 genetic variants represent major susceptibility factors for Crohn’s disease, and impaired responsiveness to bacterial peptidoglycan has been associated with altered intestinal immune regulation and chronic inflammation[1][2][7][8]. NOD2 is also connected to autophagy-related pathways and mucosal barrier function, highlighting its broader role in intestinal immune maintenance[9][10]. Compared with the related isoform NOD1, NOD2 exhibits distinct ligand specificity by recognizing MDP, whereas NOD1 preferentially detects different peptidoglycan-derived motifs, resulting in partially overlapping but non-identical innate immune functions[11]. For experimental applications, MDP remains the prototypical NOD2 agonist and is widely used to activate NOD2 signaling in cellular and animal models, while pharmacological inhibition of the downstream kinase RIPK2 has emerged as a valuable strategy for investigating NOD2-driven inflammatory mechanisms and therapeutic modulation of inflammatory bowel disease pathways[6][12][13].

References:

Productos relacionados con NOD2 (15):

Cat. No. Nombre del producto Efecto Pureza
  • HY-13682
    Mifamurtide
    		99.58%
    Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research.
  • HY-100691
    NOD-IN-1
    		Inhibitor 99.48%
    NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
  • HY-147506
    NOD2 antagonist 1
    		Antagonist 99.57%
    NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs.
  • HY-13682B
    Mifamurtide sodium
    		98.19%
    Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research.
  • HY-13682C
    Mifamurtide TFA
    		98.0%
    Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research.
  • HY-123925
    CSLP43
    		Inhibitor
    CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease.
  • HY-101927
    NOD1/2 antagonist-2
    		Antagonist
    NOD1/2 antagonist-2 (Compound 26BH) is a dual NOD1/NOD2 antagonist (IC50s: 2.36 μM and 4.16 μM for NOD1 and NOD2, respectively). NOD1/2 antagonist-2 inhibits both NF-κB and MAPK inflammatory signaling, thereby sensitizing Paclitaxel (HY-B0015) to suppress Lewis lung carcinoma growth.
  • HY-176837
    NOD2/TLR4 agonist-1
    		Agonist
    NOD2/TLR4 agonist-1 (Compound 2) is a NOD2/TLR4 dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research.
  • HY-168024
    NOD1/2-IN-1
    		Inhibitor
    NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis.
  • HY-163274
    NOD1 antagonist-1
    		Antagonist
    NOD1 antagonist-1 (compound 37) exhibits an antagonistic activity towards NOD1 and a weak NOD1/NOD2 selectivity, with IC50s of 9.18 μM and 20.8 μM, respectively.
  • HY-168159
    TLR7 agonist 27
    		Agonist
    TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic.
  • HY-168158
    NOD2 agonist 3
    		Agonist
    NOD2 agonist 3 (Compound 5) is a potent NOD2 agonist, with an EC50 of 111.45 nM. NOD2 agonist 3 shows immunopotentiating effects.
  • HY-179009
    NOD2 agonist 4
    		Agonist
    NOD2 agonist 4 (Compound 12b) is a potent NOD2 agonist with an EC50 of 44.1 nM. NOD2 agonist 4 induces cytokine production (MCP-1, IL-6 and IL-8) in peripheral blood mononuclear cells (PBMCs), both alone and in combination with Lipopolysaccharide (LPS) (HY-D1056). NOD2 agonist 4 can be used for the studies of NOD2-targeted immunomodulator or vaccine adjuvant.
  • HY-146034
    NOD1/2 antagonist-1
    		Antagonist
    NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX).
  • HY-175348
    XB2M54
    		Inhibitor
    XB2M54 is a selective XIAP antagonist. XB2M54 inhibits NOD2-mediated inflammatory signaling. XB2M54 is an E3 ligase ligand. XB2M54 can be used for synthesis of PROTAC ERα Degrader-1 (HY-112098).